Periodic Reporting for period 1 - Wirecath (Novel Catheter for the Diagnosis of Cardiovascular Disease)
Reporting period: 2019-08-01 to 2020-01-31
With this project, Cavis intends to plan further product development and large-scale clinical evaluation studies that will follow the first-in-man study. Cavis’ current research and development activities are supported by investment from shareholders and numerous innovation grants.
The company has also confirmed that its further clinical strategy will consist of three serial studies. In this respect, the team together with KOLS and cardiologist have developed two large-scale clinical study synopsis.
The strategic business review allowed for further study of the competitive landscape and led to strengthening Cavis strategy for market entry. Cavis have identified several important partners and distributors. The established strategy on how to engage with external partners will support the product’s international expansion and the company’s growth.